Home > Riviste > Minerva Pediatrics > Fascicoli precedenti > Minerva Pediatrics 2021 October;73(5) > Minerva Pediatrics 2021 October;73(5):379-82

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Minerva Pediatrics 2021 October;73(5):379-82

DOI: 10.23736/S2724-5276.16.04576-X

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Growth hormone receptor polymorphisms and growth hormone response to stimulation test: a pilot study

Sara PAGANI 1, Gianpaolo DE FILIPPO 2, Giulia GENONI 3, Domenico RENDINA 4, Cristina MEAZZA 1, Elena BOZZOLA 5, Gianni BONA 3, Mauro BOZZOLA 1

1 Unit of Pediatric and Adolescentology, Department of Internal Medicine and Therapeutics, Foundation IRCCS Polyclinic San Matteo, University of Pavia, Pavia, Italy; 2 Unit of Pediatric Endocrinology, Gaetano Rummo Hospital, Benevento, Italy; 3 Department of Health’s Sciences, University of Eastern Piedmont, Novara, Italy; 4 Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy; 5 Department of Pediatrics, Bambino Gesù Children Hospital, Rome, Italy



BACKGROUND: No gold standard pharmacological stimulation test exists for the diagnosis of growth hormone deficiency (GHD). In addition, the genetic factors that influence growth hormone (GH) responses remain unclear. This study aimed to determine whether polymorphisms in exon 6 of the GH receptor gene influence responses to the L-arginine GH stimulation test.
METHODS: This study included 27 prepubertal patients with confirmed GHD. GHD was defined as a peak GH level <8 ng/mL in response to pharmacological stimulation. The mean GH peak after L-arginine stimulation was 2.9±2.9 ng/mL.
RESULTS: The included patients had the following genotypes at the third position of codon 168: AA (N.=1), AG (N.=15) and GG (N.=11). Patients carrying the AA and AG genotypes exhibited stronger responses to arginine than patients with the GG genotype (3.1±2.7 vs. 1.5±1.3 ng/mL, P=0.01).
CONCLUSIONS: The approach employed in this study could elucidate GH profiles under physiological and pathological conditions, facilitating improved interpretation of pharmacological stimulation tests.


KEY WORDS: Polymorphism, genetic; Genes; Growth hormone

inizio pagina